论文部分内容阅读
目的探讨射频消融(radiofrequency Ablation,RFA)联合索拉非尼和干扰素治疗复发性肝癌的安全性和疗效。方法回顾性分析2006年1月~2013年12月期间69例行RFA联合索拉非尼治疗复发性肝癌患者的临床病例资料,根据是否使用干扰素分为干扰素组(n=34例)和对照组(n=35例)。比较两组患者治疗期间并发症的发生率,1、3和5年无瘤生存率和总体生存率等。结果两组患者的临床病理资料比较无统计学差异。与对照组相比,干扰素组治疗期间的并发症的发生率无明显增加(17.6%比17.1%,P=0.96)。干扰素组1、3和5年无瘤生存率分别为56.5%、21.2%和7.6%,而对照组分别为41.7%、22.7%和5.3%,组间比较差异无统计学意义(P=0.99)。干扰素组1、3和5年总体生存率分别为87.9%、45.1%和12.0%,而对照组分别为84.3%、27.4%和6.8%,组间比较差异具有统计学意义(P=0.04)。结论对于复发性肝癌患者,RFA联合索拉非尼和干扰素治疗复发性肝癌是安全、有效的,虽然不能延长患者无瘤生存率,但可提高患者的生活质量,延长患者的总体生存率。
Objective To investigate the safety and efficacy of radiofrequency ablation (RFA) combined with sorafenib and interferon in the treatment of recurrent hepatocellular carcinoma. Methods The clinical data of 69 patients with recurrent hepatocellular carcinoma treated with RFA combined with sorafenib from January 2006 to December 2013 were retrospectively analyzed. According to whether interferon was used in the interferon group (n = 34) and Control group (n = 35). The complication rates, the 1, 3, and 5 year disease-free survival rates and overall survival rates were compared between the two groups. Results There was no significant difference in clinical pathology between the two groups. Compared with the control group, there was no significant increase in the incidence of complications during the interferon treatment (17.6% vs. 17.1%, P = 0.96). The 1, 3, and 5-year disease-free survival rates in the interferon group were 56.5%, 21.2% and 7.6%, respectively, compared with 41.7%, 22.7% and 5.3% in the control group, with no significant difference between the two groups (P = 0.99 ). The overall survival rates at 1, 3, and 5 years were 87.9%, 45.1% and 12.0% in the interferon group compared with 84.3%, 27.4% and 6.8% in the control group respectively (P = 0.04) . Conclusion RFA combined with sorafenib and interferon in the treatment of recurrent hepatocellular carcinoma is safe and effective for patients with recurrent liver cancer. Although it can not prolong the patient-free survival rate, it can improve the quality of life of patients and prolong the overall survival rate of patients.